Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.

Barbanti PieroCinzia AuriliaGabriella EgeoStefania ProiettiPaola TorelliFlorindo d'OnofrioAntonio CarnevaleSofia TavaniBianca OrlandoGiulia FiorentiniBruno ColomboMassimo FilippiStefano BonassiSabina Cevolinull null

Published in: Journal of neurology (2024)

A second TrC with anti-CGRP mAbs demonstrated clinical improvements compared to the first one, as indicated by a milder migraine relapse at D2 compared to D1. Multiple TrCs with anti-CGRP mAbs could progressively modify migraine evolution by reducing CGRP-dependent neuroinflammatory nociceptive inputs to the brain.

Keyphrases

white matter
neuropathic pain
clinical trial
resting state
multiple sclerosis
functional connectivity
subarachnoid hemorrhage